FDA-aligned Phase 3 design in hand for an MSA drug with no approved rivals, but Phase 3 launch hinges on closing a partnership before Q3 2027 cash runs out

Bull

A pharmaceutical partner is secured before the Q3 2027 cash runway expires, enabling Phase 3 to initiate on the year-end 2026 timeline with a well-funded, FDA-aligned single pivotal trial design (50 mg BID, UMSARS Part I primary endpoint). This would transform Alterity from a pre-Phase 3 micro-cap into a funded registrational-stage company in an orphan neurological indication with no approved disease-modifying therapy, likely triggering a significant re-rating and providing a credible path to NDA submission.

Bear

Partnership discussions fail to close before cash is exhausted, forcing a dilutive equity raise that weakens negotiating leverage or, in a worst case, causing a trial delay that pushes initiation well beyond year-end 2026. The most likely failure modes are deal terms that cannot be agreed upon given Alterity's limited bargaining power as a small-cap cash-constrained company, or a partner concluding that the Phase 2 patient numbers (small trial, single study) are insufficient to de-risk a multi-hundred-million Phase 3 commitment in a rare, rapidly progressing disease with historically high trial failure rates.